Last checked at 19 Mar 2018 07:10
Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on March 14, 2018 at an average price of US$36.11 per ADS.
Following the above purchase, Dr Eldar is interested in 8,993 ADSs and 1,900 Ordinary Shares, representing approximately 0.0096% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||
a) |
Name |
Dr Dan Eldar
| ||||||||
2 | Reason for the notification | |||||||||
a) |
Position/status |
Non-executive Director
| ||||||||
b) |
Initial notification/Amendment
|
Initial notification
| ||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) |
Name
|
Hutchison China MediTech Limited | ||||||||
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) |
Description of the financial instrument, type of instrument Identification code
|
ADS each representing one half of one Ordinary Share of US$1.00
ADS ISIN: US44842L1035
| ||||||||
b) |
Nature of the transaction
|
Acquisition of 2,768 ADSs on March 14, 2018 at an average price of US$36.11 per ADS | ||||||||
c) |
Price(s) and volume(s) |
| ||||||||
d) |
Aggregated information
|
N/A | ||||||||
e) |
Date of the transaction |
2018-03-14
| ||||||||
f) |
Place of the transaction |
Nasdaq Stock Market
| ||||||||
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries | ||
Mark Lee, Senior Vice President, Corporate Finance & Development | +852 2121 8200 | |
U.K. & International Media Enquiries | ||
Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk |
U.S. Based Media Enquiries | ||
Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | bmiles@bmccommunications.com |
Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | sduffy@bmccommunications.com |
Investor Relations | ||
Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | mbeck@troutgroup.com |
David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | david.dible@citigatedewerogerson.com |
Panmure Gordon (UK) Limited | ||
Richard Gray / Andrew Potts | +44 (20) 7886 2500 |